Unit on Hypothalamic and Pituitary Disorders, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
Office of the Clinical Director, Eunice Kennedy Shriver National Institute of Child Health and Human development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
Pediatr Res. 2024 Feb;95(3):758-761. doi: 10.1038/s41390-023-02906-6. Epub 2023 Nov 22.
Cushing Disease (CD) is a rare endocrine disorder associated with impaired growth hormone (GH) and short stature. Insulin-like growth factor-1 (IGF-1) is a marker of GH secretion.
Patients with young onset CD (<21 years old) and available IGF-1 levels at diagnosis and/or follow-up were studied (total = 194, diagnosis = 174, follow-up = 104). IGF-1 was reported as z-score (IGF1z).
IGF1z was lower than expected in the general population (median IGF1z: -0.92 [-1.54, 0.07], p < 0.0001) at diagnosis and remained low at follow-up (median: -1.13 [-1.78, -0.66], p < 0.0001). There was no correlation of IGF1z at diagnosis with BMI; there was a weak correlation with height (r = 0.19, p = 0.035). IGF1z was inversely correlated with markers of hypercortisolemia, including morning (r = -0.31, p < 0.0001) and midnight cortisol (r = -0.30, p < 0.0001), and with insulin resistance (Homeostatic Model Assessment for Insulin Resistance, HOMA-IR, r = -0.27, p < 0.01).
IGF-1 levels in CS are on the lower side of the normal range during active disease and remain low at one year after treatment. IGF-1 levels correlated mainly with markers of hypercortisolemia rather than the short stature of patients and should not be used in the assessment of growth in this population.
We report that IGF-1 levels in childhood during active hypercortisolemia and up to 1 year after resolution are on the lower side of the normal range. Our results demonstrate that IGF-1 levels during active hypercortisolemia correlate mainly with markers of Cushing syndrome. This report adds data to the current literature where reports of IGF-1 in Cushing syndrome have shown variable results. Understanding the lack of utility of IGF-1 in assessing growth parameters in the pediatric Cushing syndrome population is important for physicians caring for these patients who should not use IGF-1 for diagnostic or treatment decisions.
库欣病(CD)是一种罕见的内分泌疾病,与生长激素(GH)受损和身材矮小有关。胰岛素样生长因子 1(IGF-1)是 GH 分泌的标志物。
研究了发病时和/或随访时有年轻起病的 CD 患者(共 194 例,诊断 174 例,随访 104 例),并检测了 IGF-1 水平。IGF-1 以 z 评分(IGF1z)报告。
诊断时 IGF1z 低于人群预期中位数(IGF1z:-0.92 [-1.54,0.07],p<0.0001),随访时仍较低中位数:-1.13 [-1.78,-0.66],p<0.0001)。IGF1z 与诊断时 BMI 无相关性;与身高有弱相关性(r=0.19,p=0.035)。IGF1z 与皮质醇过多的标志物呈负相关,包括晨峰(r=-0.31,p<0.0001)和午夜皮质醇(r=-0.30,p<0.0001),以及胰岛素抵抗(胰岛素抵抗评估的稳态模型,HOMA-IR,r=-0.27,p<0.01)。
在疾病活动期,CS 中的 IGF-1 水平处于正常范围的较低端,并且在治疗后 1 年仍较低。IGF-1 水平主要与皮质醇过多的标志物相关,而不是与患者的身材矮小相关,因此不应在该人群中用于评估生长。
我们报告称,在 ACTH 过度分泌期间和 ACTH 过度分泌解决后 1 年内,儿童时期的 IGF-1 水平处于正常范围的较低端。我们的结果表明,IGF-1 水平在 ACTH 过度分泌期间主要与库欣综合征的标志物相关。本报告增加了当前文献中的数据,其中库欣综合征的 IGF-1 报告显示结果各不相同。了解 IGF-1 在评估儿科库欣综合征人群生长参数方面的无用性对于治疗这些患者的医生非常重要,他们不应将 IGF-1 用于诊断或治疗决策。